| | | | |
FDG-SUVmax
|
FMISO-TBR
|
|---|
|
Variables
| |
Number
|
(%)
|
Mean
|
SD
|
p Value
|
Mean
|
SD
|
p Value
|
|---|
|
Number of patients
| |
44
| | | | | | | |
|
Age, years
|
Average
|
53.5
| | | | | | | |
|
(range)
|
(38–78)
| | | | | | | |
|
< 50
|
20
|
(45.4)
|
11.1
|
4.4
|
0.02
|
1.3
|
0.4
|
0.3
|
|
≥ 50
|
24
|
(45.5)
|
7.9
|
4.2
|
1.2
|
0.4
|
|
Tumor size
|
Average
|
40.9
| | | | | | | |
|
(range)
|
(14–80)
| | | | | | | |
|
< 4 cm
|
25
|
(56.8)
|
8
|
3.6
|
0.02
|
1.1
|
0.4
|
0.03
|
|
≥ 4 cm
|
19
|
(43.1)
|
11.1
|
5.1
|
1.4
|
0.4
|
|
Histology
|
IDC
|
41
|
(93.1)
|
9.6
|
4.4
|
0.1
|
1.2
|
0.4
|
0.9
|
|
Others
|
3
|
(6.8)
|
6
|
3.5
|
1.2
|
0.7
|
|
Nuclear grade
|
1/2
|
17
|
(38.6)
|
7.4
|
3.6
|
0.06
|
1
|
0.2
|
0.007
|
|
3
|
21
|
(47.7)
|
10
|
4.7
|
1.4
|
0.5
|
|
Unknown
|
6
|
(13.6)
|
–
| | |
–
|
–
| |
|
Nodal involvement
|
0
|
12
|
(27.2)
|
6.8
|
3.3
|
0.01
|
1.2
|
0.4
|
0.9
|
|
≥ 1
|
32
|
(72.7)
|
10.5
|
4.6
|
1.2
|
0.4
|
|
ER
|
+
|
26
|
(59)
|
9.1
|
4.2
|
0.7
|
1.1
|
0.3
|
0.04
|
|
–
|
18
|
(40.9)
|
9.6
|
5.1
|
1.4
|
0.5
|
|
PgR
|
+
|
19
|
(43.1)
|
7.9
|
3.1
|
0.07
|
1
|
0.2
|
0.009
|
|
–
|
25
|
(56.8)
|
10.4
|
5.2
|
1.4
|
0.5
|
|
HER2
|
+
|
7
|
(15.9)
|
7.8
|
3.6
|
0.3
|
1.2
|
0.2
|
1
|
|
–
|
37
|
(84)
|
9.6
|
4.7
|
1.2
|
0.4
|
|
Luminal A
| |
7
|
(15.9)
|
7.8
|
2.5
|
0.4
|
0.9
|
0.2
|
0.03
|
|
Luminal B
| |
16
|
(36.4)
|
9.7
|
4.8
|
1.1
|
0.3
|
|
TNBC
| |
14
|
(31.8)
|
10.5
|
5.4
|
1.4
|
0.5
|
|
HER2
| |
7
|
(15.9)
|
7.9
|
3.6
|
1.2
|
0.2
|
|
Chemotherapy
|
+
|
39
|
(88.6)
|
9.7
|
4.6
|
0.1
|
1.2
|
0.4
|
0.01
|
|
–
|
5
|
(11.4)
|
6.4
|
3
|
0.7
|
0.1
|
|
Endocrine therapy
|
+
|
26
|
(59)
|
9.1
|
4.2
|
0.7
|
1.1
|
0.3
|
0.04
|
|
–
|
18
|
(40.9)
|
9.6
|
5.1
|
1.4
|
0.5
|
- Abbreviations: FDG 18F-fluorodeoxyglucose, FMISO 18F-fluoromisonidazole, IDC Invasive ductal carcinoma, ER Estrogen receptor, PgR Progesterone receptor, TBR Tissue-to-blood ratio, TNBC Triple-negative breast cancer, HER2 Human epidermal growth factor receptor 2, SUVmax Maximum standardized uptake value
